EF-1502

Experimental drug

{{Drugbox | verifiedfields = changed | verifiedrevid = 477318123 | IUPAC_name = (2S)-2-[[4-[[4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridin-1-yl]methyl]phenoxy]methyl]morpholine | image = EF1502.svg | image2 = | width = 200 | alt = | CAS_number = 123456-78-9 | ATC_prefix = none | PubChem = 123456 | ChemSpiderID = 123456 | UNII = | KEGG = | ChEMBL = 123456 | C=21 | H=25 | Cl=1 | N=2 | O=2 | smiles = | InChI = | InChIKey = }}

EF-1502 is an experimental pharmaceutical drug that has been investigated for its potential use in the treatment of depression and anxiety disorders. It is a serotonin-norepinephrine reuptake inhibitor (SNRI) and also acts as a GABA reuptake inhibitor.

Mechanism of Action

EF-1502 functions primarily as a serotonin-norepinephrine reuptake inhibitor, which means it inhibits the reuptake of the neurotransmitters serotonin and norepinephrine in the brain. This action increases the levels of these neurotransmitters in the synaptic cleft, potentially improving mood and reducing symptoms of depression and anxiety.

Additionally, EF-1502 has been shown to inhibit the reuptake of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system. By increasing GABA levels, EF-1502 may enhance its anxiolytic effects, providing a dual mechanism of action that could be beneficial in treating anxiety disorders.

Pharmacokinetics

The pharmacokinetic profile of EF-1502 includes its absorption, distribution, metabolism, and excretion. As an orally administered drug, EF-1502 is absorbed through the gastrointestinal tract. It is then distributed throughout the body, crossing the blood-brain barrier to exert its effects on the central nervous system.

The metabolism of EF-1502 occurs primarily in the liver, where it is broken down by cytochrome P450 enzymes. The metabolites are then excreted through the renal system.

Potential Clinical Applications

EF-1502 is being studied for its potential use in treating major depressive disorder and various anxiety disorders, including generalized anxiety disorder and social anxiety disorder. Its dual mechanism of action may offer advantages over traditional antidepressants, particularly in patients who do not respond adequately to existing treatments.

Side Effects

As with many psychotropic medications, EF-1502 may cause side effects. Common side effects observed in clinical trials include nausea, headache, dizziness, and insomnia. More serious side effects could include hypertension and tachycardia, due to its action on norepinephrine reuptake.

Research and Development

EF-1502 is currently in the experimental stages of development. Clinical trials are ongoing to determine its efficacy and safety profile. The results of these trials will determine whether EF-1502 can be approved for clinical use.

Related Pages

• Serotonin-norepinephrine reuptake inhibitor
• GABA reuptake inhibitor
• Major depressive disorder
• Anxiety disorder